Morning Briefing
Summaries of health policy coverage from major news organizations
FDA Grants Biogen's Experimental Alzheimer's Drug Fast-Track Status
The treatment is in late-stage clinical trials.
The Wall Street Journal: Biogen’s Alzheimer’s Therapy Granted FDA Fast-Track Status
Biogen Inc. said its investigational therapy for the early stage of Alzheimer’s disease was granted fast-track designation by the U.S. Food and Drug Administration, a designation intended to bring promising drugs for serious conditions to market faster. ... The drug—called aducanumab—is designed to help clear the brain of beta amyloid plaques, which many scientists say play a role in causing Alzheimer’s, a progressive, memory-destroying condition associated with older age. (Stynes, 9/1)
Read more about the Alzheimer's drug some scientists are calling a game changer in the fight against the disease.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
